SCHEMBL7872336

SCHEMBL7872336

COc1ccc(NC(=O)Cc2ccccc2)cc1OC

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.80
MEN1 O00255 2/20 0.80
RAB9A P51151 3/20 0.71
NPC1 O15118 2/20 0.71
BCHE P06276 2/20 0.69
ACHE P22303 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.67
ALDH1A1 P00352 2/20 0.67
MAPT P10636 2/20 0.67
LMNA P02545 2/20 0.66
HTT P42858 1/20 0.66
USP2 O75604 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.65
HSD17B10 Q99714 2/20 0.65
EPHX2 P34913 1/20 0.64
POLB P06746 2/20 0.62
IMPDH2 P12268 1/20 0.62
AAK1 Q2M2I8 1/20 0.62
KDM4E B2RXH2 2/20 0.61
HPGD P15428 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11308885 0.87 MEN1 (0.74) KMT2AMEN1RAB9ANPC1BCHE
SCHEMBL11314927 0.87 KMT2A (0.70) KMT2AMEN1RAB9ANPC1BCHE
SCHEMBL8189434 0.85 MEN1 (0.67) KMT2AMEN1RAB9ANPC1BCHE
SCHEMBL7876671 0.85 SMN1; SMN2 (0.75) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL3653095 0.85 EPHX2 (0.77) KMT2AMEN1BCHEACHESMN1; SMN2
SCHEMBL306284 0.85 SMN1; SMN2 (0.66) KMT2AMEN1RAB9ANPC1BCHE
SCHEMBL15876305 0.84 KMT2A (0.58) KMT2AMEN1RAB9ANPC1BCHE
SCHEMBL3613697 0.84 SMN1; SMN2 (0.65) KMT2AMEN1RAB9ANPC1BCHE
SCHEMBL1581301 0.82 EPHX2 (0.61) KMT2AMEN1SMN1; SMN2ALDH1A1MAPT
SCHEMBL7101804 0.82 CYP1A2 (0.64) KMT2AMEN1BCHEACHESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6331555-B1 EVALUATING SUSCEPTIBILITY OF CANCER TO COMPOUNDS WHICH INHIBIT PLATELET DERIVED GROWTH FACTOR RECEPTOR ACTIVITY UNIVERSITY OF CALIFORNIA 2001-12-18 US disclosed
EP-1000617-A2 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor Sugen, Inc. (US) 2000-05-17 EP disclosed
US-5990141-A ADMINISTERING 5-METHYL-ISOXAZOLE-4-CARBOXYLIC ACID-N-(4-TRIFLUOROMETHYL)ANILIDE OR 2-CYANO-3-HYDROXY-N-(4-TRIFLUORO-METHYL)PHENYL-2-BUTENAMIDE; ANTITUMOR,-CARCINOGENIC AND PROLIFERATIVE AGENTS; KINASE INHIBITORS SUGEN INC. (US) 1999-11-23 US disclosed
US-5958959-A ADMINISTERING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID-(4-TRIFLUOROMETHYL)ANILIDE OR 2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)-2-BUTENAMIDE SUGEN, INC. (US) 1999-09-28 US disclosed
US-5932602-A ANTIGROWTH AGENTS; ANTITUMOR AGENT; USING AN ISOOXIDAZOLE COMPOUND SUGEN, INC. (US) 1999-08-03 US disclosed
US-5700822-A ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF ISOXAZOLE AMIDE DERIVATIOVE AND CYANO, HYDROXY, AROMATIC AMIDE DERIVATIVE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-12-23 US disclosed
US-5700823-A ADMINISTERING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID-(4-TRIFLUOROMETHYL)-ANILIDE OR N-(4-TRIFLUOROMETHYLPHENYL)-2-CYANO-3-HYDROXYCROTONAMIDE SUGEN, INC. (US) 1997-12-23 US disclosed
EP-0804191-A1 TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS USING INHIBITORS OF PLATELET DERIVED GROWTH RECEPTOR Sugen, Inc. (US) 1997-11-05 EP disclosed
WO-1995019169-A2 TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR SUGEN, INC. (US) 1995-07-20 WO disclosed